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INTRODUCTION
The retinoids, a group of vitamin A derivatives, have been
identified as potential cancer treatments and have been re-
ported to exert anti-cancer effects, which include the apop-
tosis and differentiation of cancer cells (1, 2). The major me-
tabolic forms of vitamin A in vivo are retinol, retinal, and
all-trans retinoic acid (ATRA). The 9-cis retinoic acid (RA)
and 13-cis RA are natural ATRA isomers, whereas 4-hydrox-
yphenyl retinamide (4-HPR) is a conformationally restricted
synthetic retinoid (3, 4). It has been established that ATRA
inhibits the proliferation and induces markers of apoptosis
and squamous differentiation in non-small cell lung carci-
noma (NSCLC) cell lines (5). A phase II study of ATRA as a
single agent in NSCLC showed minimal activity (8% res-
ponse rate in 28 patients) and mild toxicities (6). Moreover,
although 13-cis RA is the best-studied chemopreventive reti-
noid in the aerodigestive tract (7), 13-cis RA treatment did
not reduce the overall rates of second primary tumor devel-
opment, recurrence, or mortality in stage I NSCLC (8). 9-cis
RA is a naturally occurring ligand that exhibits a high degree
of affinity for retinoic acid receptors (RARs) and also binds
to retinoid X receptors (RXRs) (9). 9-cis RA has been observed
to have a chemopreventive effect in an A/J mouse lung car-
cinogenesis model, and this was accompanied by retinoic acid
receptor  (RAR ) upregulation (10). Kurie et al. assessed
the efficacies of two retinoid-based regimens, 9-cis RA and
13- RA+ -tocopherol, in former smokers, since the loss of
RAR expression in bronchial epithelium is considered to
be a biomarker of preneoplasia, and 9-cis RA has been report-
ed to increase RAR expression (11). 4-HPR (Fenretinide)
is a synthetic retinoid which inhibits the growths on a large
number of lung cancer cell lines, including cell lines unre-
sponsive to ATRA (12). However, no comparative study has
been conducted to determine which retinoid is most effec-
tive at causing the growth inhibition of NSCLC cells.
4-HPR acts mainly via retinoic acid receptor  (RAR ),
and in part via RAR (13). On the other hand, ATRA, 13-
cis RA, and 9-cis RA are compatible with all RARs/RXRs
subtypes (14). The major difference between 4-HPR and the
other RA derivatives is the ability to induce apoptosis; how-
ever, it does not induce cell differentiation (12). 4-HPR has
been shown to induce apoptosis in a variety of epithelial and
hematologic malignancies, but the mechanism involved has
yet to be clearly elucidated (15, 16). Two possible mechanisms
have been proposed to explain 4-HPR-induced apoptosis.
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The growth inhibitory effects of four retinoic acid (RA) derivatives, 9-cis RA, 13-cis
RA, N-(4-hydroxyphenyl) retinamide (4-HPR), and all-trans retinoic acid (ATRA)
were compared. In addition, the effects of various combinations of these four agents
were examined on non-small cell lung carcinoma (NSCLC) cell-lines, and on the
expressions of retinoic acid receptors (RARs) and retinoid X receptors (RXRs) on
these cells. At the clinically achievable concentration of 1  M, only 4-HPR inhibit-
ed the growths of H1299 and H460 cells-lines. However, retinoic acid receptor 
(RAR ) expression was up-regulated on H460 and H1299 cells treated with 1  M
of ATRA, 13-cis RA, or 9-cis RA. All NSCLC cell lines showed growth inhibition when
exposed sequentially to 1  M ATRA and 0.1  M 4-HPR. In particular, sequential
treatment with 1  M ATRA or 13-cis RA and 4-HPR markedly inhibited H1703 cell
growth; these cells exhibited no basal RAR expression and were refractory to 4-
HPR. However, in NSCLC cell lines that expressed RAR , the expressional lev-
els of RAR were up-regulated by ATRA alone and by sequential treatment with
ATRA and 4-HPR. 4-HPR was found to be the most active of the four agents in
terms of NSCLC growth-inhibition. Moreover, sequential treatments with ATRA or
13-cis RA followed by 4-HPR were found to have synergistic growth-inhibitory effects
and to regulate RAR expression.
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The first involves the participation of retinoid receptors in
4HPR-induced cellular events. This suggestion is supported
by the observations that 4-HPR-induces RAR expression
in various human carcinoma cell lines (13), and that 4-HPR
induces the activations of retinoic acid receptor  (RAR ),
RAR , and RXRs (4). The second mechanism involves the
interruption of mitochondrial membrane potentials associ-
ated with the generation of reactive oxygen species (ROS) by
4-HPR (17). Moreover, 4-HPR appears to be more robust
than ATRA with regard to its apoptosis-inducing abilities
in NSCLC cells (18). However, the possible clinical use of
4-HPR raises questions concerning the need for long-term
treatment and the safe and effective dosage required for the
long-term inhibition of cancer cell growth. Thus, novel
treatment methods are required with improved clinical effi-
cacies. In the present study, we assessed the growth inhibi-
tory effects of the four RA derivatives, 9-cis RA, 13-cis RA,
4-HPR, and ATRA, when treated singly, sequentially, and
simultaneously and compared these treatments with regard
to RAR mRNA expressional induction in NSCLC cell lines.
The other objective of this study was to determine whether
4-HPR induces apoptosis by enhancing ROS production or
by upregulating retinoid receptor expression. Thus, we con-
jectured, if 4-HPR induces apoptosis primarily via ROS gen-
eration, other retinoids, which act as antioxidants, may ex-
hibit an antagonistic effect when combined with 4-HPR.
On the other hand, if 4-HPR acts on RARs, combinations
of 4-HPR and other retinoids might result in synergism. In
this study, we show that sequential treatments with ATRA
or 13-cis RA and 4-HPR can synergistically inhibit NSCLC
cell growth via RAR regulation. From the clinical point of
view, although in vitro studies have demonstrated that 4-
HPR (at concentrations ranging from 1 to 10  M) suppresses
the growths of malignant cells of various histotypes, includ-
ing NSCLC, the mean serum level of 4-HPR in patients re-
ceiving 200 mg daily was only 0.26  M (19). Even though
a higher plasma peak level of 4-HPR could be achieved at
higher dosages, plasma peak concentrations of <3  M appear
to be safe (19). Thus, we also examined whether sequential
treatments incorporating therapeutic doses of retinoids and
low concentrations of 4-HPR synergistically cause growth
inhibitory effects in lung cancer cells, and whether these occur
via RAR or RXR pathways.
MATERIALS AND METHODS
Cell Lines and culture 
The NSCLC H460, H1299, H1703, and A549 cell lines
were obtained from the American Type Culture Collection
(ATCC, Rockville, MD, U.S.A.). H1299, H1703, and H460
cells were cultured in RPMI 1640 supplemented with 10%
fetal bovine serum (FBS), whereas A549 cells were cultured
in F12 supplemented with 10% FBS. All cell lines were grown
at 37℃ in a humidified 5% CO2 atmosphere. Cells were
seeded at 5×105 cells/10-cm plate in 10% FBS-containing
medium, but at 70% confluence were incubated for 24 hr
in 0.5% FBS-containing medium, in order to minimize the
effects of endogenous RA in culture medium. They were then
treated with retinoids for 48 hr, washed twice in phosphate-
buffered saline (PBS; pH 7.4), and collected by trypsiniza-
tion.
Reagents and treatments
ATRA, 13-cis RA, 9-cis RA, and 4-HPR were purchased
from Sigma Chemical Co. (St. Louis, MO, U.S.A.), dissolved
in 100% DMSO at 100 mM or 10 mM (4-HPR), and stored
in the dark at -80℃. We treated cell lines with these agents
to evaluate interactions between 4-HPR and the other reti-
noids in the following ways: protocol 1 (0.1  M 4-HPR
alone), protocol 2 (1  M ATRA alone), protocol 3 (0.1  M
4-HPR for 1 hr followed by 1  M of ATRA), protocol 4 (1
M ATRA for 1 hr followed by 0.1  M of 4-HPR), and pro-
tocol 5 (simultaneous treatment with 0.1  M 4-HPR plus
1 M  ATRA).  13-cis RA or 9-cis RA were examined in the
same manner as ATRA.
MTT assays 
Cellular growth rates were determined using MTT (3-[4,
5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide)
assays. Cells were grown in 96-well plates in 0.5% FBS-con-
taining medium at an initial density of 5×103 cells/well.
After 24 hr, wells were treated with various concentrations
of retinoid. After 24, 48 or 72 hr, 50  L of MTT solution
(Sigma, St. Louis, MO, U.S.A.) was added, and plates were
incubated at 37℃for 4 hr. Media and treated solutions were
then aspirated, and the formazan formed was solubilized with
150  L DMSO. Cell viabilities were measured as recommend-
ed by the manufacturer, and individual well absorbances were
measured at 540 nm using a microplate reader (BioRad, He-
rcules, CA, U.S.A.). 
RT-PCR 
Total cellular RNA was isolated from cells treated with or
without various concentrations and combinations of retinoids,
using TriReagent-RNA isolation reagent (Molecular Research
Center, Cincinnati, OH, U.S.A.), according to the manufac-
turer’s instructions. Two-microgram aliquots of total RNA
were used to generate cDNAs using Moloney murine leu-
kemia virus reverse transcriptase (MMLV; Gibco/BRL, Gai-
thersburg, MD, U.S.A.) and Oligo-d (T)15 primer (Roche,
Indianapolis, IN, U.S.A.) in a final volume of 20  L. Reac-
tion mixtures consisted of 5x first strand buffer (Gibco/BRL),
0.1 M DTT, 2.5 mM each dNTP, 2.5 units/ L MMLV, andS54 E.J. Choi, Y.M. Whang, S.J. Kim, et al.
2.5 M  Oligo-d(T)15 primer. The cDNA products (1  L) ob-
tained were then subjected to PCR to amplify RAR 2 and
-actin. The sense and antisense primers used for RAR 2
were 5′ -CAT GTT TGA CTG TAT GGA TG-3′and 5′ -
AGC CCT TAC ATC CCT CAC AG-3′ , respectively, which
produced a 329-bp PCR product, and those for  -actin (the
internal control) were 5′ -ACC CAG ATC ATG TTT GAG
ACC-3′ and 5′ -GGA GTT GAA GGT AGT TTC GTG-3′ ,
respectively, and produced a 486-bp PCR product. The PCR
reaction mixture (50  L) consisted of 1× reaction buffer, 2
mM MgCl2, 200  M dNTP, 0.4 units Han-Taq polymerase
(Genenmed, Seoul, Korea) and 0.2  M of each primer. An
initial denaturation at 94℃ for 5 min was followed by 35
amplification cycles of 94℃ for 30 sec, 50℃ for 30 sec, and
72℃for 1 min and a final extension step at 72℃for 10 min.
The PCR products obtained from each sample were then
electrophoresed on 2% agarose gel, stained with ethidium
bromide, and photographed.
Median effect analysis
Median effect analysis, using the Hill equation, was used
to determine synergistic, additive, and antagonistic effects,
when up to three agents were combined (20). H1703 cells
were incubated for 1 hr with different concentrations of AT-
RA or 13-cis RA (at 0.5, 1, 2, or 4  M), and then incubated
for 48 or 72 hr with 4-HPR (0.05, 0.1, 0.2 and 0.4  M).
The effects of sequential treatment with ATRA or 13-cis RA
and 4-HPR were determined using a dose-effect analysis
software (Biosoft, Cambridge, England). CI values indicated
synergism (CI<1), an additive effect (CI=1), or antagonism
(CI>1). 
Northern blot analysis 
Total sample cellular RNAs (10  g) were electrophoresed
on 1% agarose gel, transferred overnight to GeneScreen
Plus
� nylon membranes (NEN
�Life Science Products, Inc.,
Boston, MA, U.S.A.) by the capillary transfer method, and
then immobilized on membranes by UV crosslinking. RNA
blots were prehybridized and then hybridized to [ -32P]-
dCTP-labeled RAR cDNA probes, which were kindly donat-
ed by Dr. Jonathan M. Kurie and Dr. Ronald Evans (the Uni-
versity of Texas, M.D. Anderson Cancer Center, Houston,
Texas and the Salk Institute, San Diego, CA) (19-21). After
incubation overnight, membranes were washed under high-
stringency conditions (0.1X SSC at 65℃) and exposed over-
night (below -70℃) to radiography film for autoradiogra-
phy. Membranes were also stripped and reprobed with GA-
PDH cDNA, which was used as an RNA loading control.
Quantitative analyses were performed with a Multi-Image
light cabinet, and quantified using a Gel-doc Image analyz-
er (Bio-Rad, Hercules, CA, U.S.A.).
RESULTS
Growth inhibitory effects of retinoids on NSCLC cell lines
To compare the efficiencies of the retinoids, H460, H1299,
H1703, or A549 cells were treated with increasing concentra-
tions (0.1-10  M) of retinoids for 24, 48, or 72 hr, and then
MTT assayed. Growth inhibition was defined when treated
cells had viabilities <70% of those of untreated cells. Weak
or no growth inhibition was observed after treating either
A549 or H1703 with low or high concentrations (0.1 or 1
M, respectively) of 4-HPR (Table 1). In contrast, H1299
cell growth was inhibited by 4-HPR at both of these con-
centrations, whereas H460 cell growth was inhibited by 4-
HPR at 1  M only. At the clinically achievable concentra-
tion of 1  M, no growth inhibition was observed by treat-
ment of 9-cis RA, 13-cis RA, or ATRA in any of the four NS-
CLC cell-lines. Although the treatment with 9-cis, 13-cis RA,
or ATRA at 10  M inhibited cell growths by 30-84%, this
concentration is difficult to achieve in human serum due to
intolerable toxicity or rapid drug metabolism. 
Expression patterns of RAR in response to retinoids
In order to determine whether retinoid treatment restores
RAR expression, RAR mRNA levels in NSCLC cells
treated with retinoids were assessed by RT-PCR. Since the
pharmacologically achievable concentration of retinoids is 1
M, this concentration was used for each retinoid. Although
no growth inhibitory effect was observed after adding ATRA,
13-cis RA, or 9-cis RA at 1  M, it was found that RAR
expression was up regulated in H460 and in H1299 cells
treated with ATRA, 13-cis RA, or 9-cis RA at 1  M (Fig. 1).
Moreover, A549 cells revealed RAR expression induction
after treatment with 1  M ATRA or 1  M 9-cis RA, where-
as 1  M 13-cis RA failed to increase RAR expression in
these cells. H1299 cells and H460 cells, which showed growth
inhibition after being treated with 1  M 4-HPR, also showed
Cells were treated with one of these RA derivatives at the indicated con-
centrations. 
RA, retinoic acid; 4-HPR, 4-hydroxyphenyl retinamide; ATRA, all-trans
retinoic acid. 
RA 
derivatives
Concentra-
tions ( M)
H460
(%)
H1299
(%)
H1703
(%)
A549
(%)
4-HPR 0.1 13.48 31.28 7.23 1.53
1 33.08 61.16 16.44 12.34
9-cis RA 1 22.96 7.89 23.86 22.84
10 52.98 84.21 73.02 36.98
13-cis RA 1 12.48 5.72 8.33 16.11
10 38.72 30.49 33.17 31.12
ATRA 1 24.33 21.38 11.50 9.15
10 46.40 34.58 39.30 33.50
Table 1. The growth inhibitory effects of RA derivativesCombination of RA Derivatives in NSCLC S55
RAR expressional induction post-treatment (Table 1). More-
over, A549 cells, which were refractory to 1  M 4-HPR treat-
ment, showed brief RAR expressional induction at 24 hr
post-treatment. However, in 4-HPR refractory H1703 cells,
which showed no basal RAR expression, RAR was not
induced by 1  M 4-HPR or by the other retinoids at this
concentration. These results indicate that 1  M 4-HPR may
induce growth inhibition and induce RAR expression in
RAR -positive NSCLC cells. 
Growth inhibitory effects of combinations of 4-HPR and
other retinoids in NSCLC cell lines
To investigate the growth inhibitory effects of combina-
tional (sequential and simultaneous) treatments with 4-HPR
and other retinoids, each of the NSCLC cell lines was treat-
ed using the sequential and simultaneous protocols described
in ‘Materials and Methods’. All NSCLC cell lines showed
growth inhibition when exposed to 1  M ATRA followed
by 0.1  M 4-HPR (Fig. 2A). In particular, sequential treat-
ment with ATRA or 13-cis RA and 4-HPR (ATRA or 13-cis
RA 1  M for 1 hr followed by 4-HPR 0.1  M for 48 hr) mar-
kedly inhibited the growth of H1703 cells, which exhibited
no basal RAR expression and were refractory to 4-HPR
treatment. These results imply that the growth inhibitory
effects of 4-HPR can be facilitated by pretreating first with
other retinoids that regulate the expressions of RARs or RXRs.
Synergistic effects of sequential ATRA or 13-cis RA and
4-HPR in H1703 cells  
In order to confirm the synergistic effects of sequential
ATRA or 13-cis RA and 4-HPR, combination index (CI)
plots were drawn. Table 2 and 3 depict fractions affected
(Fa) and CI values. Plots of CI versus Fa are shown for sequen-
tial 13-cis RA or ATRA in combination with 4-HPR (ATRA
or 13-cis RA 1  M for 1 hr followed by 4-HPR 0.1  M for
48 hr or 72 hr) in H1703 cells (Fig. 3). ATRA or 13-cis RA
for 1 hr followed by 4-HPR, especially for 72 hr of 4-HPR
treatment showed consistent synergism with various com-
binations of ATRA or 13-cis RA with CI values of <1, indi-
cating synergism. 
RARs and RXRs expressions after treatment with combi-
nations of 4-HPR and retinoids (ATRA, 13-cis RA, or 9-
cis RA) in NSCLC cell lines
In order to determine whether combinational treatments of
4-HPR and other retinoids enhance RAR or RXR expressions,
northern blot analyses were performed (Fig. 4); results were
compared with those obtained for single treatments. ATRA
1  M treatment induced RAR expression in all NCSLC cell
1 M  4-HPR
RAR
329 bp
-actin
486 bp
B
l
a
n
k
CT
H1299
24 48  72  (hr)
B
l
a
n
k
CT
A549
24 48  72  (hr)
RAR
329 bp
-actin
486 bp
B
l
a
n
k
CT
H460
24 48  72  (hr)
B
l
a
n
k
CT
H1703
24 48  72  (hr)
A
1 M  9-cis RA
RAR
329 bp
-actin
486 bp
B
l
a
n
k
CT
H1299
24 48 72  (hr)
B
l
a
n
k
CT
A549
24 48 72 (hr)
RAR
329 bp
-actin
486 bp
B
l
a
n
k
CT
H460
24 48 72  (hr)
B
l
a
n
k
CT
H1703
24 48 72  (hr)
B
1 M  13-cis RA
RAR
329 bp
-actin
486 bp
B
l
a
n
k
CT
H1299
24 48  72  (hr)
B
l
a
n
k
CT
A549
24 48 72  (hr)
RAR
329 bp
-actin
486 bp
B
l
a
n
k
CT
H460
24 48  72  (hr)
B
l
a
n
k
CT
H1703
24 48 72  (hr)
C
1 M  ATRA
RAR
329 bp
-actin
486 bp
B
l
a
n
k
CT
H1299
24 48  72  (hr)
B
l
a
n
k
CT
A549
24 48 72  (hr)
RAR
329 bp
-actin
486 bp
B
l
a
n
k
CT
H460
24 48  72  (hr)
B
l
a
n
k
CT
H1703
24 48  72  (hr)
D
Fig. 1. RAR mRNA expression by RT-PCR. Cells were pretreated with 4-HPR (A), 9-cis RA (B), 13-cis RA (C), or ATRA (D) at 1  M for 48
hr. Total RNA was extracted after treating cells with each of the indicated agents for 48 hr, and the cDNA generated by MMLV reverse tran-
scriptase was subjected to PCR using specific primers for RAR messenger RNA (329 bp). The procedures used for total RNA isolation
are described in ‘Materials and Methods’.  -actin was used as an internal control. Amplified DNA was separated on 2% agarose gel and
stained with ethidium bromide.S56 E.J. Choi, Y.M. Whang, S.J. Kim, et al.
13-cis RA
dosage
4-HPR
dosage
Fraction affected CI value
0.5 M 0.05 M 0.05* 0.21
� 10.78 0.87
1 M 0.1 M 0.22* 0.56
� 1.05 0.34
2 M 0.2 M 0.52* 0.86
� 0.20 0.16
4 M 0.4 M 0.53* 0.85
� 0.37 0.35
Table 2. Median effect analysis for sequential 13-cis RA plus 4-
HPR treatment in H1703 cells
*, when cells were treated with 13-cis RA for 1 hr and then treated with
4-HPR for 48 hr. 
� , when cells were treated with 13-cis RA for 1 hr and
then treated with 4-HPR for 72 hr.
RA, retinoic acid; 4-HPR, 4-hydroxyphenyl retinamide; CI, combination
index. 
Combination of 0.1  M 4-HPR and 1  M ATRA
Combination of 0.1  M 4-HPR and 9-cis RA
Fig. 2. Effects of combinational treatments with 4-HPR and other RAs (A), 13-cis RA (B), or 9-cis RA (C). NSCLC cell lines were treated with
RAs as described in ‘Materials and Methods’. Cell survivals were determined using MTT assays. Experiments were repeated 3 times to ensure
reproducibility. Error bars are the means of 3 independently performed experiments and are shown with their respective standard deviations.
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4-HPR ATRA 4-HPR+ATRA ATRA+4-HPR 4-HPR+ATRA simultaneously
CT 4-HPR 9-cis RA 4-HPR+9 cis RA 9 cis RA+4-HPR 4-HPR+9 cis RA simultaneously
CT 4-HPR 13-cis RA 4-HPR+13-cis RA 13-cis RA+4-HPR 4-HPR+13 cis RA simultaneously
Hour Hour Hour Hour
Hour Hour Hour Hour
Hour Hour Hour Hour
ATRA 
dosage
4-HPR 
dosage
Fraction affected CI value
0.5 M 0.05 M 0.001* 0.27
� UN 0.57
1 M 0.1 M 0.09* 0.48
� 326.19 0.41
2 M 0.2 M 0.42* 0.86
� 0.02 0.33
4 M 0.4 M 0.40* 0.86
� 0.13 0.65
Table 3. Median effect analysis for sequential ATRA plus 4-HPR
treatment in H1703 cells
*, when cells were treated with ATRA for 1 hr and then treated with 4-
HPR for 48 hr. 
� , when cells were treated with ATRA for 1 hr and then
treated with 4-HPR for 72 hr.
ATRA, all-trans retinoic acid; 4-HPR, 4-hydroxyphenyl retinamide; CI,
combination index; UN, unvalued. Combination of RA Derivatives in NSCLC S57
lines and induced RAR in three cell lines (except H1703).
In the other NSCLC cell lines, which showed basal RAR
expression, RAR expressional levels were up regulated by
1  M ATRA alone or by sequentially treating with 1  M
ATRA and 0.1  M 4-HPR (Fig. 4B). In contrast, RAR
expression was induced by 1  M ATRA in all NSCLC cell
lines, but these inductions of RAR were lost by simulta-
neously or sequentially treating ATRA and 4-HPR in all
four NSCLC cell lines (Fig. 4C). 
Basal RAR -positive NSCLC cell lines revealed RAR
expressional induction after 0.1  M 4-HPR treatment, whe-
reas H1703 cells, which did not exhibit RAR basal expres-
sion, showed reduced RAR expression after treatment with
0.1  M 4-HPR. The synergistic growth inhibition shown
by H1703 cells sequentially treated with ATRA 1  M for 1
hr followed by 4-HPR 0.1  M for 48 hr was accompanied
by reduced RAR expression. Moreover, this sequential treat-
ment with 4-HPR prevented the upregulation of RAR by
ATRA. These findings indicate that sequential treatment
with other retinoids and 4-HPR may cause growth inhibi-
tion due to the modulation of RAR expressions by the ini-
tially treated retinoids. 
DISCUSSION
The retinoids are a class of natural and synthetic vitamin A
analogues, and some retinoids are known to play major roles
in cell growth regulation and in the differentiation of nor-
mal, benign, and malignant cell types. Retinoids are among
the most intensively studied cancer chemoprevention agents.
However, the broad biological activities of the retinoids lead
to a number of undesirable side effects, which limits their
long-term clinical usefulnesses as chemopreventatives (21).
13-cis RA was found to be effective at reversing upper
aerodigestive tract premalignancies (22) and at preventing
second primary tumor development in advanced head and
neck cancer (23), but its administration was also associated
with significant toxicity. In terms of lung cancer treatment,
the United States Intergroup Study found no benefit for 13-
cis RA intervention in individuals with a prior history of lung
cancer (8). In the present study, no growth inhibitory effects
were observed on therapeutic (1  M) dosages of ATRA or
13-cis RA, although RAR expression was found to be up-
regulated in NSCLC cell lines after ATRA or 13-cis RA treat-
ment.
9-cis RA, a natural ATRA isomer, is a pan-agonist that is
able to bind to and activate both RXRs and RARs. 9-cis RA
can activate RXR/RAR heterodimers, RXR/RXR homod-
imers, and other nuclear receptor complexes in which RXR
is a ligand-binding partner, such as, vitamin D receptor and
peroxisome proliferator-activated receptors (24). Thus, by
virtue of its unique receptor-binding properties, 9-cis RA
exerts biological effects that differ from those of ATRA or
13-cis RA. In a recent study, 9-cis RA was found to up regu-
late RAR expression in bronchial squamous metaplasia
(11), which suggests that 9-cis RA is a potential chemopre-
ventive agent in NSCLC. However, in the present study, 9-
cis RA inhibited NSCLC cell growth only at higher than
clinically acceptable concentrations.
4-HPR, despite its inability to bind directly to nuclear
receptors, shows some preventive activity in experimental
animals, and was also found to be active in lung cancer cell
lines, where it inhibited growth and induced apoptosis. How-
ever, 4-HPR does not induce cell differentiation as in RAs,
but rather induces apoptosis (12, 25, 26), which is not effec-
tively induced by RAs. ROS production, the RAR/RXR
pathway, and a variety of mechanisms yet to be elucidated
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can mediate 4-HPR-induced apoptosis. Moreover, several
previous reports have indicated that 4-HPR is far more po-
tent than ATRA in terms of inducing NSCLC cell apopto-
sis, thus indicating the need for further preventative and
therapeutic trials (18). Although in vitro studies have demon-
strated that 4-HPR (at concentrations ranging from 1 to 10
M) suppresses the growth of NSCLC cells, and that these
effects are associated with apoptotic induction, 4-HPR was
not effective at reversing squamous metaplasia, dysplasia, or
genetic and phenotypic abnormalities in the bronchial epithe-
lium of smokers (27). This inactivity of 4-HPR with respect
to pathologic changes in bronchial mucosa raised the possi-
bility that serum 4-HPR levels in this previous study were
too low to achieve a biological effect. The apoptotic effects
of 4-HPR in tissue cultures typically require 4-HPR con-
centrations of >1  M (18). A phase I trial of 4-HPR in chil-
dren with neuroblastoma demonstrated that high-dose 4-
HPR was well tolerated up to 4,000 mg/m2/day (19). The
highest dose examined in this trial produced an average drug
plasma level of 12.9  M, and an association was found bet-
ween plasma peak levels and toxicity-associated side effects.
After repeated treatments, plasma peak concentrations of
<3  M appeared to be safe. Moreover, the frequency of grade
2-3 toxicity was found to be significantly higher in patients
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Fig. 4. Northern analysis of the expressions of RARs after treating
NSCLC cell lines with 4-HPR and other retinoids (ATRA, 13-cisRA,
or 9-cisRA) singly or in combination. Cells were treated as des-
cribed above. For Northern analysis, 10  g of total RNA was sub-
jected to electrophoresis in agarose gel and blotted onto a nylon
membrane. H460 was a RAR positive control. GAPDH was used
as an internal loading control. Blotting procedures are described
in ‘Materials and Methods’. Densities (%) of the RAR expressions
are expressed as density ratios versus control (CT) levels. Combination of RA Derivatives in NSCLC S59
with peak levels exceeding 3  M (19). In the present study,
the growth inhibitory effect of 4-HPR in NSCLC cell lines
was interesting, because, although no growth inhibitory
effects were observed in A549 or H1703 cells with 0.1  M
treatment, 4-HPR inhibited the growths of all four NSCLC
cell lines tested at the clinically relevant concentration of 1
M, and in fact, H1299 cells were even inhibited at 0.1  M.
Recently, ROS generation has been implicated in 4-HPR-
induced apoptosis in some malignant cells (28). Low doses
of ROS, particularly of hydrogen peroxide, are known to be
mitogenic and to promote cell proliferation, whereas high
levels of oxidative stress ultimately cause cell death via apop-
totic or necrotic mechanisms (29). Thus, if 4-HPR induces
apoptosis primarily by inducing ROS production, 4-HPR
could have antagonistic effects when co-administered with
ATRA, 13-cis RA, or 9-cis RA, as these species are antioxi-
dants (14). Conversely, if 4-HPR mainly acts on RAR, com-
binations of 4-HPR and other retinoids may act synergisti-
cally.
4-HPR binds to retinol-binding protein in the liver, and
therefore competes with retinol and reduces serum retinol
levels (30). Thus, loss of serum retinol may counterbalance
the chemopreventive effects of 4-HPR, and the effect of 4-
HPR might be enhanced by restoring normal retinol levels
by administering 4-HPR in combination with other retinoids
(27).
The growth inhibitory effects of retinoid treatments in all
NSCLC cells examined were greater when the cells were ex-
posed to 1  M ATRA followed by 0.1  M 4-HPR. H1703
cells, which do not show RAR basal expression, were not
sensitive to 4-HPR treatment alone. However, sequential
treatment with ATRA or 13-cis RA followed by 4-HPR syn-
ergistically inhibited H1703 cell growth. Moreover, these
growth inhibitions were accompanied by reduced RAR
expression on H1703 cells, when the cells were treated with
4-HPR alone or with sequential ATRA or 13-cis RA and 4-
HPR. RAR expression also was lower in cells treated with
sequential ATRA/4-HPR than in cells treated with ATRA
alone in all NSCLC cell lines. Since these cells showed RAR
up regulation after a single ATRA treatment, 4-HPR appears
to act in concert with the up regulated RAR expression
induced by ATRA but to override the effect of ATRA when
they are administered sequentially. The ATRA/4-HPR com-
bination has been examined in other cancer cells. Lim et al.
investigated whether 4-HPR (due to its suppression of HER2/
neu and/or EGFR expression) sensitized breast cancer cells
to ATRA, and found that at a concentration of 1.3  M, 4-
HPR increased ATRA sensitivity in a synergistic manner in
BT-474, MDA-MB-453, and MCF-7/HER2 breast cancer
cells (31). Another study demonstrated the efficacy of 4-HPR
in mice bearing the human ovarian carcinoma IGROV-1,
and demonstrated that 4-HPR significantly enhanced the
antitumor activity of cisplatin. In IGROV-1 tumor-bearing
mice, a simultaneous RA/4-HPR combination was found
to significantly improve the efficacy of 4-HPR, and resulted
in an antitumor activity similar to that of cisplatin alone.
These findings demonstrate that the simultaneous RA/4-
HPR combination may increase the antitumor activity of 4-
HPR (32). 
We conclude that sequential ATRA or 13-cis RA and 4-
HPR treatments offer a valid therapeutic approach to the
treatment or chemoprevention of NSCLC via RAR expres-
sional modulation. Moreover, this approach could overcome
4-HPR refractoriness in NSCLC cells. Further work is war-
ranted to determine the identities of the molecular signals
underlying the synergistic and additive effects of RAs.
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